These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15279572)

  • 1. Beta-lactam cholesterol absorption inhibitors.
    Burnett DA
    Curr Med Chem; 2004 Jul; 11(14):1873-87. PubMed ID: 15279572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
    Dražić T; Sachdev V; Leopold C; Patankar JV; Malnar M; Hećimović S; Levak-Frank S; Habuš I; Kratky D
    Bioorg Med Chem; 2015 May; 23(10):2353-9. PubMed ID: 25882530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption.
    Kvaernø L; Werder M; Hauser H; Carreira EM
    J Med Chem; 2005 Sep; 48(19):6035-53. PubMed ID: 16162006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.
    Burnett DA; Caplen MA; Domalski MS; Browne ME; Davis HR; Clader JW
    Bioorg Med Chem Lett; 2002 Feb; 12(3):311-4. PubMed ID: 11814785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of 3-(aryl)alkenyl-beta-lactams by an efficient application of olefin cross-metathesis on solid support.
    Testero SA; Mata EG
    Org Lett; 2006 Oct; 8(21):4783-6. PubMed ID: 17020302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.
    Burnett DA; Caplen MA; Browne ME; Zhau H; Altmann SW; Davis HR; Clader JW
    Bioorg Med Chem Lett; 2002 Feb; 12(3):315-8. PubMed ID: 11814786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.
    Howell KL; DeVita RJ; Garcia-Calvo M; Meurer RD; Lisnock J; Bull HG; McMasters DR; McCann ME; Mills SG
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6929-32. PubMed ID: 21030254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective cholesterol absorption inhibition as a new prospect in treatment of hypercholesterolemia].
    Lima J; Fonollosa V; Chacón P
    Med Clin (Barc); 2005 Jun; 125(1):16-23. PubMed ID: 15960941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal sterol transporters and cholesterol absorption inhibition.
    Davis HR; Tershakovec AM; Tomassini JE; Musliner T
    Curr Opin Lipidol; 2011 Dec; 22(6):467-78. PubMed ID: 22101558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezetimibe (Schering-Plough).
    Meng CQ
    Curr Opin Investig Drugs; 2001 Mar; 2(3):389-92. PubMed ID: 11575710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors.
    Ritter T; Kvaernø L; Werder M; Hauser H; Carreira EM
    Org Biomol Chem; 2005 Oct; 3(19):3514-23. PubMed ID: 16172689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.
    Davis HR; Veltri EP
    J Atheroscler Thromb; 2007 Jun; 14(3):99-108. PubMed ID: 17587760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ezetimibe: from pharmacology to clinical trials].
    Tellier P
    Ann Endocrinol (Paris); 2003 Dec; 64(6):442-7. PubMed ID: 15067249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption].
    Márk L; Paragh G
    Orv Hetil; 2007 Apr; 148(14):627-32. PubMed ID: 17403635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461.
    Salisbury BG; Davis HR; Burrier RE; Burnett DA; Bowkow G; Caplen MA; Clemmons AL; Compton DS; Hoos LM; McGregor DG
    Atherosclerosis; 1995 May; 115(1):45-63. PubMed ID: 7669087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on patented cholesterol absorption inhibitors.
    Chhabria MT; Mahajan BM
    Expert Opin Ther Pat; 2009 Aug; 19(8):1083-107. PubMed ID: 19552506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
    Dražić T; Molčanov K; Sachdev V; Malnar M; Hećimović S; Patankar JV; Obrowsky S; Levak-Frank S; Habuš I; Kratky D
    Eur J Med Chem; 2014 Nov; 87():722-34. PubMed ID: 25305716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of intestinal cholesterol absorption by ezetimibe in humans.
    Sudhop T; Lütjohann D; Kodal A; Igel M; Tribble DL; Shah S; Perevozskaya I; von Bergmann K
    Circulation; 2002 Oct; 106(15):1943-8. PubMed ID: 12370217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.